News
(2)April 2026
ACRS Annual Report Details Pipeline Progress and Financial Runway
# 🧾 What This Document Is This filing is the **Annual Report to Shareholders (ARS)** for Aclaris Therapeutics for the year ending December 31, 2025. Think of it as a company's official, comprehensive yearly report card sent directly to its owners (the shareholders). It's designed to be a detailed
Aclaris Therapeutics (ACRS) Sets Virtual Meeting for Director and Pay Votes
# 🧾 What This Document Is This is a **DEF 14A**, also known as a **Proxy Statement**. Think of it as an official invitation and information packet for Aclaris Therapeutics' upcoming shareholder meeting. Its main job is to give shareholders the details they need to vote on important company decision
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.